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Summary
Background Membranous nephropathy leads to end-stage renal disease in more than 20% of patients. Although 
immunosuppressive therapy beneﬁ ts some patients, trial evidence for the subset of patients with declining renal 
function is not available. We aimed to assess whether immunosuppression preserves renal function in patients with 
idiopathic membranous nephropathy with declining renal function. 
Methods This randomised controlled trial was undertaken in 37 renal units across the UK. We recruited patients 
(18–75 years) with biopsy-proven idiopathic membranous nephropathy, a plasma creatinine concentration of less 
than 300 μmol/L, and at least a 20% decline in excretory renal function measured in the 2 years before study entry, 
based on at least three measurements over a period of 3 months or longer. Patients were randomly assigned (1:1:1) by 
a random number table to receive supportive treatment only, supportive treatment plus 6 months of alternating cycles 
of prednisolone and chlorambucil, or supportive treatment plus 12 months of ciclosporin. The primary outcome was 
a further 20% decline in renal function from baseline, analysed by intention to treat. The trial is registered as an 
International Standard Randomised Controlled Trial, number 99959692.
Findings We randomly assigned 108 patients, 33 of whom received prednisolone and chlorambucil, 37 ciclosporin, 
and 38 supportive therapy alone. Two patients (one who received ciclosporin and one who received supportive 
therapy) were ineligible, so were not included in the intention-to-treat analysis, and 45 patients deviated from 
protocol before study end, mostly as a result of minor dose adjustments. Follow up was until primary endpoint or 
for minimum of 3 years if primary endpoint was not reached. Risk of further 20% decline in renal function was 
signiﬁ cantly lower in the prednisolone and chlorambucil group than in the supportive care group (19 [58%] of 
33 patients reached endpoint vs 31 [84%] of 37, hazard ratio [HR] 0·44 [95% CI 0·24–0·78]; p=0·0042); risk did not 
diﬀ er between the ciclosporin (29 [81%] of 36) and supportive treatment only groups (HR 1·17 [0·70–1·95]; 
p=0·54), but did diﬀ er signiﬁ cantly across all three groups (p=0·003). Serious adverse events were frequent in all 
three groups but were higher in the prednisolone and chlorambucil group than in the supportive care only group 
(56 events vs 24 events; p=0·048).
Interpretation For the subset of patients with idiopathic membranous nephropathy and deteriorating excretory renal 
function, 6 months’ therapy with prednisolone and chlorambucil is the treatment approach best supported by our 
evidence. Ciclosporin should be avoided in this subset.
Funding Medical Research Council, Novartis, Renal Association, Kidney Research UK.
Introduction
Membranous nephropathy is the most common cause of 
primary nephrotic syndrome in adults, and according to 
ﬁ gures from the Netherlands,1 30–50 people per million 
population develop the disorder every 5 years (6–10 per 
million population per year). Membranous nephropathy 
results in substantial mor bidity and is an important 
cause of end-stage renal disease, which accounted for 
expen diture of US$40 bil lion in the USA in 2008.2 
Optimum treatment for mem branous nephropathy is 
controversial despite several controlled trials having 
assessed available treatments, not least because the 
disorder has a variable natural history and many severely 
aﬀ ected individuals can undergo spontaneous remission. 
Only a subset of patients (25–30% in most series) 
develops progressive loss of kidney function, and since 
available therapies have substantial adverse eﬀ ects, 
some believe that aggressive therapy should be reserved 
for this subgroup.3,4 However, no large prospective ran-
dom ised controlled trials (RCTs) in this worst-aﬀ ected 
subset exist.
Studies of the natural history of membranous neph-
ropathy show that once excretory renal function starts 
to decline, continued deterioration can be expected,5 
which suggests that the really important clinical 
question in mem branous nephropathy is whether 
treatments that are eﬀ ective in less severely aﬀ ected 
patients are also beneﬁ cial in patients showing deﬁ nite 
signs of decline in renal function.6,7 Thus, ﬁ ndings 
from prospective RCTs are essen tial to inform decisions 
about treatment of this disorder.
Idiopathic membranous nephropathy is often man-
aged with immunosuppressive drugs. Until recently, 
evidence that this nephropathy is autoimmune in 
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origin was circumstantial.8 However, autoantibodies to 
the phospholipase A2 receptor (PLA2R1) have now been 
noted in most aﬀ ected individuals,9 and a predisposition 
to the disorder has been very strongly linked to two 
genetic regions (one in the MHC and the other in the 
PLA2R1 gene itself10)—ﬁ ndings that support an im-
munological pathogenesis and provide a rationale for 
immunosuppressive therapy, especially treatment tar-
geted at B lymphocytes.
When our study was designed, combined treatment 
with prednisolone and chlorambucil11 and single-agent 
therapy with ciclosporin were supported by RCT evi-
dence.12 We did a questionnaire survey as part of our 
preliminary research and noted that nephrologists were 
uncertain about the relative risks of intervention with 
immunosuppressive therapy compared with supportive 
therapy alone. There fore, we aimed to test the hypothesis 
that immuno suppressive therapy, either with prednis-
olone and chloram bucil or with ciclosporin, preserves 
renal function in patients with idiopathic membranous 
nephropathy with de clining renal function compared 
with supportive therapy alone.
Methods
Trial design and participants
In this randomised controlled trial, patients were recruited 
from 37 of 45 renal units in acute hospitals throughout the 
UK that obtained local ethical approval. Inclusion criteria 
were: age 18–75 years; biopsy-proven diagnosis of mem-
branous nephropathy (we did not impose a limit on the 
time since biopsy), regarded as idiopathic with no evidence 
of an underlying cause (such as drugs, infections, or 
tumours); and serum or plasma creatinine concen tration 
of less than 300 μmol/L together with a 20% or greater 
decline in excretory renal function (measured by 
creatinine clear ance or estimated with the Cockcroft-Gault 
calculation, and later by the Modiﬁ cation of Diet in Renal 
Disease [MDRD] formula13) that was based on at least 
three measurements over a period of 3 months or longer 
within the 2 years before study entry.
We excluded patients whose membranous nephropathy 
was a result of secondary causes (deﬁ ned according to 
usual clinical practice). Other exclusion criteria were: 
known infection with hepatitis B or C virus or HIV; 
known malignant disease; positive antibodies to double-
stranded DNA; current treatment with gold, penicil-
lamine, non-steroidal anti-inﬂ ammatory drugs, cytotoxic 
drugs, or ciclosporin; more than 3 months’ treatment 
with corticosteroids in the preceding 2 years; pregnancy 
or unreliable contraception; or a previous adverse 
reaction to prednisolone, methylprednisolone, chloram-
bucil or ciclosporin.
Ethics approval was obtained from the South West 
Multicentre Research Ethics Committee (reference 
MREC/97/6/12). Each participating centre also obtained 
local ethical approval. All patients gave written 
informed consent.
Randomisation
Eligible patients were randomly assigned by a member of 
staﬀ  in the clinical trials oﬃ  ce at the Glasgow Royal 
Inﬁ rmary, Glasgow, UK, who was not otherwise involved 
in the trial. A random numbers table had been prepared to 
allocate patients to one of three groups: sup portive therapy 
alone, supportive therapy plus 6 months of prednisolone 
and chlorambucil, or supportive therapy plus 12 months 
of ciclosporin. Treatment allocation was communicated by 
fax to the clinician entering the patient into the trial. We 
did not attempt to mask patients or investigators.
Procedures
We recorded baseline data for the supportive treatment 
alone group at randomisation, because these patients 
were eﬀ ectively continuing their existing management. In 
the two groups receiving immunosuppressive treat ment 
in addition to supportive therapy, baseline data were 
recorded when the new treatment began. We could not 
always start immunosuppressive treat ment immediately 
after randomisation because the new treatments had to be 
prescribed and delivered. 
The treatment schedules were based on best available 
evi dence at the time. All patients received supportive 
therapy, including renin-angiotensin blockade, statins, 
and anticoagulants as indicated. Those assigned to 
supportive therapy plus 6 months’ prednisolone and 
chorambucil11 received intravenous methyl prednisolone 
1 g per day for 3 consecutive days then oral prednisolone 
0·5 mg/kg per day for 28 days during months 1, 3, and 5. 
Intravenous prednisolone was administered in hos pital. 
During months 2, 4, and 6, patients received oral chlor-
ambucil at a starting dose of 0·15 mg/kg per day. We 
gave this reduced dose because the parent drug and its 
metabolites are renally excreted and our preliminary 
work14 had shown that a dose of 0·2 mg/kg per day was 
poorly tolerated in patients with impaired excretory renal 
function. We reduced the dose further if the patient 
developed leucopenia (weekly full blood counts were 
advised) and interrupted it if leucopenia was severe.
Those assigned to supportive therapy plus 12 months’ 
of ciclosporin received a starting dose of 5 mg/kg per 
day,12 adjusted according to trough blood concen trations 
of the drug to achieve a concentration of 100–200 μg/L. 
We reduced the dose if toxicity was evident.
We followed up patients until they met the primary 
endpoint, or for a minimum of 3 years if they did not do 
so. The trial was not formally analysed until 3 years after all 
patients had begun treatment. All surviving trial patients 
remain under routine follow-up at their renal units.
The primary endpoint was a further 20% decline in 
excretory renal function from baseline readings, cal-
culated in all patients with the Cockcroft-Gault equation 
(standard methodology at the start of the trial).
Secondary endpoints were proteinuria (measured with 
24-h urinary collections or estimated from protein–
creatinine ratios by multiplying the ratio [in mg/mmol] 
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by 10) and severe adverse events. The primary investigator 
(PWM) identiﬁ ed which adverse events were serious and 
cat egorised them according to the most aﬀ ected body 
system. We report all serious adverse events as deﬁ ned 
by the Medicines and Healthcare products Regulatory 
Agency (MHRA) guidance15—(ie, any adverse event, 
adverse reaction, or unexpected adverse reaction that 
results in death, is life-threatening, results in admission 
to hospital or extends the length of an existing hospital 
stay, results in persistent or serious disability or 
incapacity, or consists of a congenital anomaly or birth 
defect). We also regarded as serious other important 
medical events that might have jeopardised the patient or 
needed intervention to prevent one of these outcomes. 
We recorded information about deaths and development 
of end-stage renal disease.
In accordance with the Medical Research Council’s 
guidelines for good clinical practice, a trial steering 
committee and a data monitoring committee were estab-
lished to receive yearly reports for primary endpoints, 
adverse events, and deaths. 
Statistical analysis
To have 90% power to detect a reduction in frequency of 
the primary endpoint from 80% in the supportive 
treatment group to 40% in the immunosuppression 
groups with p<0·05, we calculated that 35 patients would 
be needed in each group (105 in total). After allowing for 
an estimated dropout rate of 10%, we concluded that we 
needed to recruit 116 patients.
Primary analysis followed the principles of intention to 
treat, and secondary analysis assessed all patients who 
received at least one dose of treatment. Unless otherwise 
stated, p values and estimates of treatment eﬀ ects are 
based on two-way comparisons. We did not make 
adjustments for multiple comparisons. We analysed 
time to further 20% decline in renal function by the log-
rank test and calculated hazard ratios [HRs] with Cox 
proportional hazards regression. We used the log-rank 
test for other survival endpoints, and repeated measures 
analysis of variance fowr continuous longitudinal data 
(eg, proteinuria). We analysed serious adverse event data 
with the log-rank test on the basis of time to ﬁ rst serious 
adverse event. We did statistical analyses using SAS 
software (version 9.2).
In 2003, the trial was shown to comply with the 
requirements of the EU clinical trials directive, and in 
Figure 1: Trial proﬁ le
108 randomly assigned
38 assigned to supportive therapy alone
1 did not meet inclusion criteria
37 eligible patients assigned to supportive
therapy alone 
37 received allocated intervention  
0 did not receive allocated intervention
3 lost to follow-up
1 major deviation from protocol
1 withdrawn by physician
2 minor deviations from protocol
37 analysed by intention to treat
37 assigned to ciclosporin33 assigned to prednisolone and chlorambucil
1 did not meet inclusion criteria
33 eligible patients assigned to prednisolone
and chlorambucil
32 received allocated intervention
1 received ciclosporin
36 eligible patients assigned to ciclosporin
35 received allocated intervention
1 received prednisolone and chlorambucil
36 analysed by intention to treat33 analysed by intention to treat
0 lost to follow-up
11 major deviation from protocol
9 temporary cessations because
of toxicity 
2 had >2 months delay 
between randomisation and 
start of treatment 
9 minor deviations from
protocol
2 lost to follow-up
6 major deviations from protocol
6 temporary cessations because
of toxicity
11 minor deviations from protocol
Prednisolone and 
chlorambucil (n=33)
Ciclosporin (n=36) Supportive therapy 
only (n=37)
Creatinine clearance (mL/min) 50 (16) 49 (18) 50 (20)
Systolic blood pressure (mm Hg) 141 (16) 143 (21) 138 (19)
Proteinuria (g per 24 h) 10·1 (5·3) 6·8 (4·7) 9·1 (5·3)
Age (years) 58 (12) 58 (11) 56 (16)
Time of baseline reading*
<2 weeks before randomisation 0 0 3 (8%)
>2 weeks after randomisation 11 (33%) 11 (31%) 1 (3%)
Data are mean (SD) or number (%). *Baseline readings were taken at start of study treatment in  the 
immunosuppressive treatment groups.
Table 1: Baseline values
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2004, a clinical trial authorisation (CTA) was obtained 
from the Medicines and Healthcare products Regulatory 
Authority (CTA number 18524/0001/001). In 2008, the 
trial was adopted onto the National Institute for Health 
Research portfolio and assigned the UK Clinical Re-
search Network identiﬁ cation number 2579. The trial is 
registered as an International Standard Randomised 
Controlled Trial, number 99959692.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility to submit for publication.
Results
We randomly assigned 108 patients between April 1, 1998, 
and March 31, 2008, at a steady rate of about one patient 
per month (ﬁ gure 1). We discovered that two patients were 
ineligible after ran domisation, so no follow-up data are 
available for them, and they weren’t included in the 
primary analysis. Of the 106 patients included in the 
intention-to-treat analysis, 37 were assigned to receive 
supportive therapy alone, 33 to prednisolone and chloram-
bucil, and 36 to ciclosporin. 37 of the 45 centres that 
obtained ethics approval entered patients into the trial.
The groups had similar baseline measurements (table 1). 
Times between randomisation and baseline readings are 
longer in both immunosuppressive groups than in the 
supportive therapy alone group because of delays relating 
to prescription, delivery, and admin istration of treatment. 
We classed deviations from the deﬁ ned protocol, 
including starting dose of intervention drugs, as either 
minor (eg, dose reductions because of toxicity) or major 
(eg, cessation of treatment, including temporary inter-
ruptions, or administration of the wrong treatment). We 
did not classify a delay between randomisation and start 
of treatment as a default protocol deviation. How ever, 
two patients had excessive delays (2 and 3 months, 
respectively), and we classiﬁ ed both as major deviations. 
Angiotensin-converting enzyme inhibitor was given to 
27 (82%) of 33 in the prednisolone and chlorambucil 
group, 36 (100%) of 36 patients in the ciclosporin group, 
and 34 (92%) of 37 of those who received supportive 
treatment only. We did not obtain information about 
angiotensin-receptor antagonist use.
The rate of occurrence of a further 20% decline in 
excretory renal function from baseline was fastest in the 
ciclosporin group and slowest in the prednisolone and 
chlorambucil group (ﬁ gure 2). Risk of a further 20% 
decline in renal function was signiﬁ cantly lower in the 
prednisolone and chlorambucil group than in the 
supportive therapy group (19 [58%] of 33 patients vs 
31 [84%] of 37 patients, HR 0·44 [95% CI 0·24–0·78]; 
p=0·0042), with no signiﬁ cant diﬀ erence noted between 
the ciclosporin group (29 [81%] of 36 patients) and 
supportive care group (HR 1·17 [0·70–1·95]; p=0·54). The 
diﬀ erence in the proportion of patients who reached the 
primary endpoint across all three groups was signiﬁ cant 
(p=0·003 for the three-way comparison; ﬁ gure 2).
Survival analysis showed no signiﬁ cant diﬀ erences 
between groups: two (6·1%) of 33 patients in the 
prednisolone plus chlorambucil group died during the 
trial follow-up compared with two (5·6%) of 36 patients 
in the ciclosporin group and one (2·7%) of 37 in the 
supportive therapy group. We did not classify any deaths 
as likely to be related to trial treatments. Of the ﬁ ve 
deaths, two were due to myocardial infarction (one each 
in the prednisolone plus chlor ambucil and ciclosporin 
groups), one to septicaemia (in the supportive treatment 
only group), and two to unknown causes.
Malignant disease was reported in two (6·1%) of 
33 patients in the prednisolone plus chlorambucil group 
during follow-up: one had squamous-cell carcinoma of 
the skin and one had adenocarcinoma of the sigmoid 
Figure 2: Kaplan-Meier analysis of further 20% decline in renal function
Deaths were censored. GFR=glomerular ﬁ ltration rate.
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colon. 11 patients reached end-stage renal disease: one 
(3·0%) of 33 in the prednisolone plus chlorambucil group 
compared with six (16·7%) of 36 in the ciclosporin group 
and four (10·8%) of 37 in the supportive therapy group.
The fall in proteinuria with time was greatest in the 
prednisolone plus chlorambucil group (ﬁ gure 3). The 
diﬀ erence in the mean reduction of protein in the urine 
for prednisolone and chlorambucil versus supportive 
therapy alone was −2·2 g in 24 h (p=0·014). The 
diﬀ erence in the mean reduction for ciclosporin versus 
supportive care alone was −0·7 g in 24 h (p=0·46).
We recorded 390 adverse events, of which 117 were 
deemed serious by PWM. These 117 events occurred in 
54 patients (table 2). The number of patients with a 
serious adverse event by 1 year did not diﬀ er signiﬁ cantly 
between the ciclosporin and supportive care groups 
(17 [46%] of 37 patients in the ciclosporin group vs 
11 [29%] of 38 in the supportive therapy only group; 
p=0·20), but the number of patients in the prednisolone 
and chlorambucil group with a serious adverse event by 
1 year (17 [52%] of 33 patients) was signiﬁ cantly higher 
than in the supportive care group (p=0·048).
Haematological events were leucopenia, anaemia, 
and thrombocytopenia, although we did not note any 
lymphomas or leukaemias. Dermatological eﬀ ects in-
cluded rash and shingles. Renal eﬀ ects were mainly 
deterioration of excretory renal func tion or hyper-
kalaemia. Neurological eﬀ ects were tremor and headache. 
Cardiovascular eﬀ ects were hypertension, myocardial 
infarction, chest pain, and pulmonary em bolus. Meta-
bolic eﬀ ects included impairment of glucose tolerance. 
Gastroenterological eﬀ ects included nausea, vomiting, 
diarrhoea, bleeding, and pancreatitis. Infection included 
septicaemia, pneumonia, and cellulitis. Other eﬀ ects 
included cataract, fractured humerus, hernia repairs, and 
pulmonary sarcoid. We acknowledge that some potential 
adverse eﬀ ects of prednisolone plus chlorambucil and 
ciclosporin are more longlasting than the eﬀ ects reported 
with supportive care alone, especially the risk of 
lymphoma or other malignant diseases.
Discussion
These results suggest that supportive therapy plus 
prednisolone and chlorambucil is better at prevention of 
decline in excretory renal function than is supportive 
therapy plus ciclosporin or supportive therapy alone in 
patients with deteriorating function due to idiopathic 
membranous nephropathy. Ideally the results should be 
Figure 3: Change in measured or calculated 24-h urinary protein
Datapoints show mean change in 24-h urinary protein from baseline; error bars show 95% CI. The numbers of patients from whom readings were taken at each 
timepoint are presented; variation in numbers was due to dropout and missing readings at those timepoints. 
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Ciclosporin Supportive therapy 
only
Patients with at least one SAE* 20/33 (61%) 18/37 (49%) 16/38 (42%)
Number of SAEs† 56/117 (48%) 37/117 (32%) 24/117 (21%)
Likelihood to be related to treatment‡§
None/unlikely 20/56 (36%) 18/37 (49%) 24/24 (100%)
Possible 10/56 (18%) 6/37 (16%) 0
Likely 26/56 (46%) 13/37 (35%) 0
Body system aﬀ ected
Haematological 28 5 3
Dermatological 4 2 0
Renal 1 5 2
Neurological 3 6 4
Cardiovascular 4 3 3
Metabolic 8 1 5
Gastroenterological 3 3 2
Infection 3 8 2
Other/not speciﬁ ed 2 4 3
Data are number, or number (%). SAE=serious adverse event. *Out of number of patients assigned to each treatment 
group; includes patients removed from the intention-to-treat analysis because they were deemed ineligible after 
randomisation. †Out of number of SAEs overall. ‡Out of number of SAEs in each treatment group. §Likelihood was 
assessed by PWM.
Table 2: Serious adverse events by treatment and body system aﬀ ected
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conﬁ rmed in a larger study, but because this trial took 
10 years to recruit due to the diﬃ  culty of running a 
multicentre trial in slowly progressive glomerular dis-
ease, a similar larger study is unlikely to be done. 92% of 
all patients in this trial received angiotensin-converting 
enzyme inhibitors, showing that this aspect of supportive 
therapy was virtually universal in all three groups. The 
beneﬁ t to renal function was matched by a reduction in 
proteinuria with prednisolone and chlorambucil. In this 
severely aﬀ ected subset of patients, we thought it would 
be unlikely that even responders would achieve complete 
remission of proteinuria, hence our decision to make 
excretory renal function our primary endpoint.
Adverse events were frequent, including in the sup-
portive therapy group, suggesting that this group of 
patients is susceptible to major medical problems. 
Masking was impossible because of the nature of the 
treatments involved, but we accept that the fact that the 
study was unblinded might have aﬀ ected the reporting of 
adverse eﬀ ects. In the active intervention groups, the 
serious adverse eﬀ ects were predictable from the side-
eﬀ ect proﬁ les of the drugs—particularly headache, tremor, 
hypertension, deterioration in renal function, or infection 
in the ciclosporin group and predominantly haemato-
logical (especially leucopenia and anaemia) or metabolic 
(espe cially glucose intolerance) eﬀ ects in the prednisolone 
and chlorambucil group. Dose adjustment of chlor-
ambucil arose frequently and treatment inter ruptions 
were common, both accounting for most of the protocol 
departures in the prednisolone and chloram bucil group. 
Similarly, in the ciclosporin group, nephro toxicity was a 
substantial problem despite the fact that we used target 
blood concentrations advocated in a previous RCT;12 dose 
reductions, treatment inter ruptions, and reaching of 
primary end point were frequent in this group.
Slow trial recruitment was undoubtedly determined by 
the eligibility criteria: deteriorating renal function in 
idiopathic membranous nephropathy has become less 
common with angiotensin-cascade blockade and other 
aspects of supportive management,16 and our detailed 
communications with renal units throughout the UK 
during the trial showed that the rarity of eligible patients 
was the main barrier to recruitment. Of the 37 units that 
entered patients, 31 recruited four patients or fewer. 
Renal units that declined to participate and apply for 
ethical approval were roughly equally divided into those 
concerned about the lack of active therapy in the 
supportive care only group or the potential toxicity 
of active therapy—clear evidence that consider able 
uncertainty surrounds appropriate management of this 
disorder, and that a deﬁ nitive RCT is needed. 
We contend that for patients with idiopathic mem-
branous nephropathy, 6 months’ therapy with alternat ing 
monthly cycles of prednisolone and chlorambucil is the 
treatment approach best supported by evidence, and our 
study extends this evidence to the important subset of 
patients with membranous nephropathy and deteriorating 
excretory renal function. Our ﬁ ndings do not support the 
use of ciclosporin in this group—the adverse eﬀ ects on 
renal function make it unsuitable once renal function has 
started to decline. The ciclosporin starting dose in our 
study was based on an RCT reported by Cattran and 
colleagues.12 A later trial led by this group17 used a lower 
starting dose (3·5 mg/kg per day) but aimed for similar 
plasma concentrations and reported beneﬁ cial eﬀ ects on 
proteinuria. Other investigators have used a lower dose of 
ciclosporin in small un controlled studies and also 
reported beneﬁ cial eﬀ ects for proteinuria.18,19
Shortly after our study started, Ponticelli and col-
leagues20 reported that the choice of alkylating agent 
(between chlorambucil and the more familiar cyclo-
phosphamide) for idiopathic membranous nephropathy 
might be immaterial, although cyclophos phamide might 
be less toxic. We decided not to change our study design, 
but we agree that cyclophosphamide could probably be 
substituted for chlorambucil. Uncon trolled studies using 
a combination of prednisolone and cyclophosphamide in 
severely aﬀ ected patients have led to similar conclu-
sions,1,21 and one RCT supports this approach in patients 
with well preserved renal function at entry.22 Our study 
shows that this form of therapy can still be eﬀ ective in 
patients whose renal function has started to deteriorate. 
The use of alkylating agents (with their potent eﬀ ects on 
B lymphocytes) for idiopathic membranous nephropathy 
has a rationale now that autoantibodies to PLA2R1 have 
been discovered in most patients.8,9 Immunosuppressive 
therapy is also logical in view of our previously published 
analysis of the genetic basis of idiopathic membranous 
nephropathy,10 showing that two genes predispose white 
people to this disorder, an immune-response gene in the 
HLA-DQA1 region and the PLA2R1 gene itself.
Rituximab for idiopathic membranous nephropathy 
has shown promise,23,24 but so far evidence for its 
eﬀ ectiveness is not based on RCT data and the 
beneﬁ cial eﬀ ects are mostly in reduction of proteinuria 
rather than preservation of excretory renal function. 
Furthermore, rituximab is expensive and is associated 
with important long-term safety concerns such as 
progressive multifocal leukoencephalopathy.25 However, 
progressive multifocal leu koencephalopathy has not 
been reported in patients with idiopathic membranous 
nephropathy given rituxi mab and might be associated 
with intensity of immuno suppression, since patients 
who got the disease received rituximab together with 
other agents. Future RCTs should assess the cost-
eﬀ ectiveness, eﬃ  cacy, and safety of rituximab for 
patients with idiopathic mem branous nephropathy, 
perhaps compared with prednis olone plus an alkylating 
agent (either cyclophosphamide or chlorambucil). 
Future trials should ideally include patient-reported 
outcomes and an analysis of the balance between 
treatment costs (including those associated with 
adverse eﬀ ects) and costs of renal replacement therapy 
in untreated patients, so that the cost–beneﬁ t of 
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delaying the need for renal replacement therapy and 
quality-of-life issues can be assessed.
Adverse eﬀ ects, particularly haematological outcomes, 
were common in patients given prednisolone and 
chloram bucil in our study and often necessitated dose 
reduction or inter ruption of therapy. Clearly, the preser-
vation of renal function that can be achieved with 
prednisolone and chlorambucil comes at a price, and 
careful monitoring of the therapy is needed.
Beneﬁ ts of prednisolone and chlorambucil were 
maintained for at least 3 years of follow-up. Delaying 
end-stage renal disease, with its associated cardio vascular 
risk and increased morbidity and mortality, is of 
undoubted value to patients with idiopathic mem branous 
nephropathy. However, even in patients given predniso-
lone and chlorambucil, only 40% had not had a further 
20% decline in excretory renal function at 3 years. Clearly, 
more eﬀ ective and safer forms of therapy are still needed 
for idiopathic membranous nephropathy. Until new 
treat ments are available and have been properly tested, 
the evidence favours use of prednisolone and an 
alkylating agent in the most severely aﬀ ected patients. 
This conclusion, and the lack of good RCTs in nephrology 
to address this and similar questions, are supported by a 
Cochrane review of the subject26 and an authoritative 
review of the international scientiﬁ c literature on the 
treatment of glomerulo nephritis (panel).27
The supportive therapy only group eﬀ ectively con tinued 
current treatment whereas the two intervention groups 
received new treatment, which led to some minor 
diﬀ erences in the time between randomisation and 
baseline readings (ie, initiation of treatment); however, 
the time diﬀ erences were small in the context of this 
slowly progressive disease in comparison with the length 
of follow-up, and as a result the risk of bias is small.
Recruitment was very slow and the trial was designed 
over 14 years ago. However, we believe that the trial results 
are still relevant, not least because few RCTs of drugs for 
this disease have been done, with none in the subset of 
patients with deteriorating excretory renal function.
One aspect of the slow recruitment was the changes 
in methods that became established during the trial, both 
for estimation of excretory kidney function and assessment 
of proteinuria. We used one consistent method for the 
calculation of primary endpoints. We did not use gold-
standard methods of measuring kidney function such as 
isotope clearance studies. These methods are expensive 
and invasive, and although our trial depended on esti-
mations, we believe it is relevant to everyday clinical 
practice since we used standard estimation techniques 
that are used in nephrology practice worldwide.
In this study we assessed ciclosporin monotherapy and 
noted that the drug’s nephro toxicity, even at blood 
concentrations advocated in a previous RCT,12,15 was 
harmful in the severely aﬀ ected subset that we selected. 
Some physicians advocate use of ciclosporin together 
with prednisolone, but we know of no good evidence that 
this combination reduces renal toxicity.
We need to follow up these patients for even longer 
to absolutely assess the value of the delay to end-stage 
renal disease that we noted in the prednisolone and 
chlorambucil group and to gather longer-term data for 
delayed adverse eﬀ ects in the two intervention groups, 
especially lymphomas and other malignancies.
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